Coloplast Balans Gezondheid

Financiële gezondheid criteriumcontroles 2/6

Coloplast heeft een totaal eigen vermogen van DKK7.0B en een totale schuld van DKK20.8B, wat de schuld-eigenvermogensverhouding op 295.4% brengt. De totale activa en totale passiva bedragen respectievelijk DKK35.3B en DKK28.3B. De EBIT Coloplast is DKK7.0B waardoor de rentedekking 18.9 is. Het heeft contanten en kortetermijnbeleggingen van DKK644.0M.

Belangrijke informatie

295.4%

Verhouding schuld/eigen vermogen

DKK 20.78b

Schuld

Rente dekkingsratio	18.9x
Contant	DKK 644.00m
Aandelen	DKK 7.03b
Totaal verplichtingen	DKK 28.27b
Totaal activa	DKK 35.30b

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( DKK9.3B ) van 0QBO N } dekken niet de korte termijn passiva ( DKK9.4B ).

Langlopende schulden: De kortetermijnactiva van 0QBO N ( DKK9.3B ) dekken de langetermijnschulden ( DKK18.8B ) niet.

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 286.3% ) 0QBO N wordt als hoog beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van 0QBO N is de afgelopen 5 jaar gestegen van 59.2% naar 295.4%.

Schuldendekking: De schuld van 0QBO N wordt goed gedekt door de operationele kasstroom ( 23.6% ).

Rentedekking: De rentebetalingen op de schuld van 0QBO N worden goed gedekt door EBIT ( 18.9 x dekking).

Coloplast Balans Gezondheid

Financiële gezondheid criteriumcontroles 2/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Coloplast A/S Recommends the Distribution of Year-End Dividend

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/S Announces Interim Dividend for the First Half of 2023/24, Payable on May 15, 2024

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Coloplast A/S Approves the Distribution of Year-End Dividend

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Less than half of directors are independent

First quarter 2023 earnings released: EPS: kr.5.31 (vs kr.5.67 in 1Q 2022)

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

Less than half of directors are independent

Coloplast Announces Executive Changes

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

Coloplast Launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023

Coloplast A/S Provides Revenue Guidance for the Fiscal Year 2021-2022

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Less than half of directors are independent

Coloplast A/S Provides Earnings Guidance for the Full Year of 2022

Contraline Names Yelena Tropsha as CTO

Less than half of directors are independent

Coloplast A/S (CPSE:COLO B) completed the acquisition of Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners.

First quarter 2022 earnings: Revenues exceed analyst expectations

Coloplast A/S Updates Earnings Guidance for the Year 2021/22

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Upcoming dividend of kr.14.00 per share

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Coloplast A/S Provides Earnings Guidance for the Year 2020/2021

Coloplast A/S Provides Earnings for the Year 2021

Investor sentiment improved over the past week

Coloplast A/S Elects Marianne Wiinholt as A New Member of the Board of Directors

Upcoming Dividend of kr.13.00 Per Share

Coloplast A/S (CPSE:COLO B) acquired Nine Continents Medical, Inc. for approximately $150 million.

Coloplast A/S to Report First Half, 2021 Results on May 06, 2021

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven